{"id":2598,"date":"2018-10-01T12:02:00","date_gmt":"2018-10-01T10:02:00","guid":{"rendered":"https:\/\/der-arzneimittelbrief.com\/artikel\/2018\/statine-zur-primaerpraevention-nur-bis-zum-75-lebensjahr"},"modified":"2018-10-01T12:02:00","modified_gmt":"2018-10-01T10:02:00","slug":"statine-zur-primaerpraevention-nur-bis-zum-75-lebensjahr","status":"publish","type":"post","link":"https:\/\/der-arzneimittelbrief.com\/artikel\/2018\/statine-zur-primaerpraevention-nur-bis-zum-75-lebensjahr","title":{"rendered":"Statine zur Prim\u00e4rpr\u00e4vention nur bis zum 75. Lebensjahr?"},"content":{"rendered":"<p>Eine Kohortenstudie aus Katalonien greift ein wichtiges, aber von der klinischen Forschung vernachl\u00e4ssigtes Thema auf: die Pr\u00e4vention kardiovaskul\u00e4rer Erkrankungen (CVD) bei \u00e4lteren Menschen mittels Statinen. W\u00e4hrend die Leitlinien Statine in der Sekund\u00e4rpr\u00e4vention (bei Hochrisiko) unabh\u00e4ngig vom Alter empfehlen, sind die Empfehlungen zur Prim\u00e4rpr\u00e4vention uneinheitlich. Ob \u00fcberhaupt, ab welchem Grundrisiko und wie lange mit Statinen behandelt [&hellip;]<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Eine Kohortenstudie aus Katalonien greift ein wichtiges, aber von der klinischen Forschung vernachl\u00e4ssigtes Thema auf: die Pr\u00e4vention kardiovaskul\u00e4rer Erkrankungen (CVD) bei \u00e4lteren Menschen mittels Statinen. W\u00e4hrend die Leitlinien Statine in der Sekund\u00e4rpr\u00e4vention (bei Hochrisiko) unabh\u00e4ngig vom Alter empfehlen, sind die Empfehlungen zur Prim\u00e4rpr\u00e4vention uneinheitlich. Ob \u00fcberhaupt, ab welchem Grundrisiko und wie lange mit Statinen behandelt [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[684,349,495,60,1272,1046,1274,451,449,155,1166,1715,1716,71,68,455,453,498,456,454,65,801,1043,56,505,443,520],"class_list":["post-2598","post","type-post","status-publish","format-standard","hentry","category-allgemein","tag-akutes-koronarsyndrom","tag-alter","tag-angina-pectoris","tag-apoplektischer-insult","tag-arteriosklerose","tag-atorvastatin","tag-cholesterin","tag-cholesterinsynthese-hemmer","tag-cse-hemmer","tag-diabetes-mellitus-typ-2","tag-fluvastatin","tag-geriatrie","tag-geriatrische-patienten","tag-herzinfarkt","tag-hirninfarkt","tag-hmg-coa-reduktase-hemmer","tag-hypercholesterinaemie","tag-koronare-herzkrankheit","tag-lipidsenker","tag-lovastatin","tag-myokardinfarkt","tag-pravastatin","tag-rosuvastatin","tag-schlaganfall","tag-simvastatin","tag-statine","tag-verordnungsverhalten"],"_links":{"self":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/2598","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/comments?post=2598"}],"version-history":[{"count":0,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/2598\/revisions"}],"wp:attachment":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/media?parent=2598"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/categories?post=2598"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/tags?post=2598"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}